Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Immunicum AB (publ) Presents Further Preclinical Ilixadencel Mode of Action Data at Annual SITC Meeting

Immunicum AB
Posted on: 07 Nov 17
Press Release

07 November 2017

Immunicum AB (publ) Presents Further Preclinical Ilixadencel Mode of Action Data at Annual SITC Meeting

Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel, immune-priming cancer treatment against a variety of solid tumors, today announced the presentation of results from a preclinical study designed to provide further data on lead drug candidate ilixadencel's mode of action. The preclinical results show how ilixadencel induces complementary immunological processes that are needed in order to prime the immune system to recognize and destroy cancer cells. The results will be presented in a poster at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting, held November 8-12, 2017 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland.

Immunicum in collaboration with Professor Magnus Essand's research group at Uppsala University conducted a series of cell culture experiments designed to mimic the immunological processes that arise when ilixadencel is injected intratumorally and subsequently interact with a cancer patient's immune system.

The poster titled " In vitro mode of action of ilixadencel - a cell-based allogeneic immune primer for intratumoral administration " will be presented on November 11 at 12.30 pm EST by Dr. Karlsson-Parra.

As demonstrated by the data, the following immunological processes were induced:

  1. Ilixadencel, when cultured on its own, produced substantial amounts of cell-signaling molecules (chemokines and cytokines) that are crucial for attracting and activating key immune cells, specifically the patient's dendritic cells, natural killer (NK) cells and T cells.
  2. Ilixadencel, when co-cultured with NK cells, induced the production of high levels of IFN-gamma which is an important stimulatory factor required for activation of tumor-specific killer T cells.
  3. Ilixadencel was also shown to significantly increase the ability of the NK cells to kill tumor cells.
  4. The specific inflammatory factors produced in cocultures of ilixadencel and immune cells were further shown to induce phenotypic and functional maturation of dendritic cells, which is important for the immune system to recognise the tumor cells.

By boosting these complementary mechanisms, ilixadencel increases the capacity of the immune system to more efficiently recognize and destroy tumor cells.

"We are excited about these data which broaden our understanding of the underlying mechanisms of how ilixadencel works and are consistent with what we have previously seen," said Alex Karlsson-Parra, Chief Scientific Officer of Immunicum. "The ability of ilixadencel to activate NK cells into highly efficient tumor cell killers is of particular interest since NK cell-mediated tumor cell death is known to facilitate the subsequent priming of tumor-specific T cells. We appreciate the opportunity to share these findings with the scientific and medical community attending the SITC."

The conference abstracts were published today on the SITC website. The full poster will be available following the presentation on Immunicum's website through this link: http://immunicum.se/investors/downloads/

Immunicum's lead program ilixadencel is currently in clinical development in an ongoing Phase 2 trial in renal cell carcinoma (MERECA) as well as a Phase 1/2 study in gastrointestinal stromal tumors and has successfully completed Phase 1/2 studies in renal cell carcinoma and hepatocellular carcinoma with a favourable safety profile and evidence of tumor-specific immune activation in the majority of patients.

About ilixadencel
Ilixadencel cell therapy product (formerly known as INTUVAX ® ) is an off-the-shelf cancer immune primer, developed for the treatment of solid tumors. Its active ingredient is activated allogeneic dendritic cells, derived from healthy blood donors. Intratumoral injection of these cells is expected to lead to an inflammatory response which in turn leads to tumor-specific activation of the patient's cytotoxic T-lymphocytes.

For more information, please contact:

Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com

Investor Relations Sweden

Helena Stångberg
Hallvarsson & Halvarsson
Telephone: + 46 709 71 12 53
E-mail: ir@immunicum.com

Investor and Media Relations EU/US

MacDougall Biomedical Communications
Gretchen Schweitzer or Stephanie May
Telephone: +49 89 2424 3494 or +49 175 5711562
E-mail:  ir@immunicum.com

The Company's Certified Adviser is Redeye AB
Telephone: +46 (0)8 545 013 30
www.redeye.se

 

About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq First North Premier. www.immunicum.com

 

 



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Immunicum AB via GlobeNewswire
HUG#2147365
GlobeNewswire
globenewswire.com

Last updated on: 08/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.